Apremilast, an orally taken phosphodiesterase 4 inhibitor, tofacitinib, a Janus kinase inhibitor, and numerous new biologics that target the IL-23 and IL-17 pathways, such as secukinumab, or brodalumab, or ixekizumab, and also ustekinumab, are among the latest psoriatic arthritis medications [16]. The gene discussed is IL37; the disease is psoriatic arthritis.